CCN2 plays a key role in extracellular matrix gene expression in severe hypertrophic cardiomyopathy and heart failure

Journal of Molecular and Cellular Cardiology

Volumn 62, Issue , 2013, Pages 164-178

  Tsoutsman, Tatiana ^a,b   Wang, Xiaoyu ^b   Garchow, Kendra ^c   Riser, Bruce ^c,d   Twigg, Stephen ^b,e   Semsarian, Christopher ^a,b,e  

^a CENTENARY INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d BAXTER HEALTHCARE CORPORATION   (United States)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Cardiomyopathy; CCN2; Fibrosis; Genetics; Heart failure

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; MMP3 PROTEIN; REGULATOR PROTEIN; TIMP1 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CCN2 GENE; CONTROLLED STUDY; DISEASE SEVERITY; EXTRACELLULAR MATRIX; FN1 GENE; GENE; GENE EXPRESSION; GENE MUTATION; HEART FAILURE; HEART MUSCLE CELL; HYPERTROPHIC CARDIOMYOPATHY; IN VITRO STUDY; MALE; MMP14 GENE; MOUSE; NONHUMAN; POSTN GENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SERPIN3A GENE; SERPINE1 GENE; SERPINEE2 GENE; SPP1 GENE; THBS1 GENE; THBS4 GENE; TIMP1 GENE; TNC GENE; TRANSFORMING GROWTH FACTOR BETA1 GENE; TRANSFORMING GROWTH FACTOR BETA2 GENE; UPREGULATION;

CARDIOMYOCYTES; CARDIOMYOPATHY; CCN2; CM; CONNECTIVE TISSUE GROWTH FACTOR (CTGF); ECM; EXTRACELLULAR MATRIX; FIBROSIS; GENETICS; HCM; HEART FAILURE; HYPERTROPHIC CARDIOMYOPATHY; NEONATAL VENTRICULAR CARDIOMYOCYTES; NM; NON-MYOCYTES; NON-TRANSGENIC; NTG; NVCM;

ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC; CELLS, CULTURED; CONNECTIVE TISSUE GROWTH FACTOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HEART FAILURE; HEART VENTRICLES; IMMUNOHISTOCHEMISTRY; MALE; MICE; MYOCYTES, CARDIAC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84879489505     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.05.019     Document Type: Article

References (30)

1. Maron B.J., Maron M.S., Semsarian C. Genetics of hypertrophic cardiomyopathy after 20years: clinical perspectives. J Am Coll Cardiol 2012, 60:705-715.
2. Ho C.Y. Hypertrophic cardiomyopathy in 2012. Circulation 2012, 125:1432-1438.
3. Teekakirikul P., Padera R.F., Seidman J.G., Seidman C.E. Hypertrophic cardiomyopathy: translating cellular cross talk into therapeutics. J Cell Biol 2012, 199:417-421.
4. Frangogiannis N.G. Matricellular proteins in cardiac adaptation and disease. Physiol Rev 2012, 92:635-688.
5. Teekakirikul P., Eminaga S., Toka O., Alcalai R., Wang L., Wakimoto H., et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta. J Clin Invest 2010, 120:3520-3529.
6. Tsoutsman T., Kelly M., Ng D.C., Tan J.E., Tu E., Lam L., et al. Severe heart failure and early mortality in a double-mutation mouse model of familial hypertrophic cardiomyopathy. Circulation 2008, 117:1820-1831.
7. Girolami F., Ho C.Y., Semsarian C., Baldi M., Will M.L., Baldini K., et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. J Am Coll Cardiol 2010, 55:1444-1453.
8. Ingles J., Doolan A., Chiu C., Seidman J., Seidman C., Semsarian C. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet 2005, 42:e59.
9. McLennan S.V., Wang X.Y., Moreno V., Yue D.K., Twigg S.M. Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy. Endocrinology 2004, 145:5646-5655.
10. Duisters R.F., Tijsen A.J., Schroen B., Leenders J.J., Lentink V., van der Made I., et al. miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 2009, 104:170-178. [6p following 8].
11. Bagnall R.D., Tsoutsman T., Shephard R.E., Ritchie W., Semsarian C. Global microRNA profiling of the mouse ventricles during development of severe hypertrophic cardiomyopathy and heart failure. PLoS One 2012, 7:e44744.
12. Tsoutsman T., Bagnall R.D., Semsarian C. Impact of multiple gene mutations in determining the severity of cardiomyopathy and heart failure. Clin Exp Pharmacol Physiol 2008, 35:1349-1357.
13. Tsoutsman T., Chung J., Doolan A., Nguyen L., Williams I.A., Tu E., et al. Molecular insights from a novel cardiac troponin I mouse model of familial hypertrophic cardiomyopathy. J Mol Cell Cardiol 2006, 41:623-632.
14. Geisterfer-Lowrance A.A., Christe M., Conner D.A., Ingwall J.S., Schoen F.J., Seidman C.E., et al. A mouse model of familial hypertrophic cardiomyopathy. Science 1996, 272:731-734.
15. Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
16. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3. [RESEARCH0034].
17. Ball D.K., Rachfal A.W., Kemper S.A., Brigstock D.R. The heparin-binding 10kDa fragment of connective tissue growth factor (CTGF) containing module 4 alone stimulates cell adhesion. J Endocrinol 2003, 176:R1-R7.
18. Wang X., McLennan S.V., Allen T.J., Tsoutsman T., Semsarian C., Twigg S.M. Adverse effects of high glucose and free fatty acid on cardiomyocytes are mediated by connective tissue growth factor. Am J Physiol Cell Physiol 2009, 297:C1490-C1500.
19. Leask A., Parapuram S.K., Shi-Wen X., Abraham D.J. Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease?. J Cell Commun Signal 2009, 3:89-94.
20. Sonnylal S., Shi-Wen X., Leoni P., Naff K., Van Pelt C.S., Nakamura H., et al. Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. Arthritis Rheum 2010, 62:1523-1532.
21. Panek A.N., Posch M.G., Alenina N., Ghadge S.K., Erdmann B., Popova E., et al. Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS One 2009, 4:e6743.
22. Ahmed M.S., Gravning J., Martinov V.N., von Lueder T.G., Edvardsen T., Czibik G., et al. Mechanisms of novel cardioprotective functions of CCN2/CTGF in myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2011, 300:H1291-H1302.
23. Ohnishi H., Oka T., Kusachi S., Nakanishi T., Takeda K., Nakahama M., et al. Increased expression of connective tissue growth factor in the infarct zone of experimentally induced myocardial infarction in rats. J Mol Cell Cardiol 1998, 30:2411-2422.
24. Adam O., Lavall D., Theobald K., Hohl M., Grube M., Ameling S., et al. Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. J Am Coll Cardiol 2010, 55:469-480.
25. Kelly D., Khan S., Cockerill G., Ng L.L., Thompson M., Samani N.J., et al. Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail 2008, 10:133-139.
26. Zachariah J.P., Colan S.D., Lang P., Triedman J.K., Alexander M.E., Walsh E.P., et al. Circulating matrix metalloproteinases in adolescents with hypertrophic cardiomyopathy and ventricular arrhythmia. Circ Heart Fail 2012, 5:462-466.
27. Eguchi T., Kubota S., Kawata K., Mukudai Y., Uehara J., Ohgawara T., et al. Novel transcription-factor-like function of human matrix metalloproteinase 3 regulating the CTGF/CCN2 gene. Mol Cell Biol 2008, 28:2391-2413.
28. Chen M.M., Lam A., Abraham J.A., Schreiner G.F., Joly A.H. CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol 2000, 32:1805-1819.
29. Wu Q., Kuo H.C., Deng G.G. Serine proteases and cardiac function. Biochim Biophys Acta 2005, 1751:82-94.
30. Maquerlot F., Galiacy S., Malo M., Guignabert C., Lawrence D.A., d'Ortho M.P., et al. Dual role for plasminogen activator inhibitor type 1 as soluble and as matricellular regulator of epithelial alveolar cell wound healing. Am J Pathol 2006, 169:1624-1632.